Skip to main content Accessibility help
  • Print publication year: 2016
  • Online publication date: May 2016

Chapter 7 - Progressivesupranuclear palsy and corticobasal degeneration in the FTD spectrum

from Section 2 - Clinical phenotypes

Related content

Powered by UNSILO
1. Pick, A. Über die Beziehungen der senilen Hirnatrophie zur Aphasie. Prager Med Wochenschr 1892;17:165–7.
2. von Braunmühl, A. Krankheit, Picksche. In: Bumke, O, ed. Handbuch der Geisteskrankheiten. Vol. 11. Part VII. Berlin, Germany: Springer-Verlag. 1930;673715. [German].
3. Akelaitis, AJ. Atrophy of basal ganglia in Pick's disease. Arch Neurol Psychiatry 1944;51:2734.
4. Steele, JC, Richardson, JC, Olszewski, J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brainstem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333–59.
5. Rebeiz, JJ, Kolodny, EH, Richardson, EP. Corticodentatonigral degeneration with neuronal achromasia. A progressive disorder of late adult life. Trans Am Neurol Assoc 1967;9:23–6.
6. Gibb, WR, Luthert, PJ, Marsden, CD. Corticobasal degeneration. Brain 1989;112:1171–92.
7. Rebeiz, JJ, Kolodny, EH, Richardson, EP Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968;18:2033.
8. Constantinidis, J, Richard, J, Tissot, R. Pick's disease. Histological and clinical correlations. Eur Neurol 1974;11 (4):208–17.
9. Munoz-Garcia, D, Ludwin, SK. Classic and generalized variants of Pick's disease: a clinicopathological, ultrastructural, and immunocytochemical comparative study. Ann Neurol 1984;16 (4):467–80.
10. Neary, D, Snowden, JS, Gustafson, L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51 (6):1546–54.
11. The Lund and Manchester Groups. Consensus statement. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994;57:416–18.
12. McKhann, GM, Albert, MS, Grossman, M, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001;58:1803–9.
13. Kertesz, A, McMonagle, P, Blair, M, Davidson, W, Munoz, DG. The evolution and pathology of frontotemporal dementia. Brain 2005;128:19962005.
14. Spillantini, MG, Goedert, M. Tau mutations in familial frontotemporal dementia. Brain 2000;123:857–9.
15. Yamada, T, McGeer, PL, McGeer, EG. Appearance of paired nucleated, tau-positive glia on patients with progressive supranuclear palsy brain tissue. Neurosci Lett 1992;135:99102.
16. Feany, MB, Dickson, DW. Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 1995;146 (6):1388–96.
17. Komori, T, Arai, N, Oda, M, et al. Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol 1998;96 (4):401–8.
18. Goedert, M, Spillantini, MG, Potier, MC, Ulrich, J, Crowther, RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 1989;8 (2):393–9.
19. Goedert, M, Wischik, CM, Crowther, RA, Walker, JE, Klug, A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA 1988;85 (11):4051–5.
20. Goode, BL, Chau, M, Denis, PE, Feinstein, SC. Structural and functional differences between 3-repeat and 4-repeat tau isoforms. Implications for normal tau function and the onset of neurodegenerative disease. J Biol Chem 2000;275 (49):38182–9.
21. Arai, T, Ikeda, K, Akiyama, H, et al. Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol 2004;55 (1):72–9.
22. Baker, M, Litvan, I, Houlden, H, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999;8 (4):711–15.
23. Di Maria, E, Tabaton, M, Vigo, T, et al. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol 2000;47 (3):374–7.
24. Pittman, AM, Myers, AJ, Abou-Sleiman, P, et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet 2005;42 (11):837–46.
25. Rademakers, R, Melquist, S, Cruts, M, et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet 2005;14 (21):3281–92.
26. Schellenberg, GD. A genome-wide association study of progressive supranuclear palsy and corticobasal degeneration: genes that modify risk. Dement Geriatr Cogn Disord 2010;30 (Suppl 1):1819.
27. Donker Kaat, L, Boon, AJ, Azmani, A, et al. Familial aggregation of parkinsonism in progressive supranuclear palsy. Neurology 2009;73 (2):98105.
28. Borroni, B, Goldwurm, S, Cerini, C, et al. Familial aggregation in progressive supranuclear palsy and corticobasal syndrome. Eur J Neurol 2011;18(1):195–7.
29. Schrag, A, Ben-Shlomo, Y, Quinn, NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross sectional study. Lancet 1999;354:1771–5.
30. Armstrong, MJ, Litvan, I, Lang, AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80 (5):496503.
31. Litvan, I, Agid, Y, Calne, D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47 (1):19.
32. Boeve, BF. Progressive supranuclear palsy. Parkinsonism Relat Disord 2012;18(Suppl 1):S192–4.
33. Rohrer, JD, Lashley, T, Schott, JM, et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 2011;134:2565–81.
34. Dickson, DW, Kouri, N, Murray, ME, Josephs, KA. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci 2011;45 (3):384–9.
35. Wakabayashi, K, Takahashi, H. Pathological heterogeneity in progressive supranuclear palsy and corticobasal degeneration. Neuropathology 2004;24 (1):7986.
36. Williams, DR, Lees, AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009;8 (3):270–9.
37. Osaki, Y, Ben-Shlomo, Y, Lees, AJ, et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord 2004;19 (2):181–9.
38. Hughes, AJ, Daniel, SE, Ben-Shlomo, Y, Lees, AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861–70.
39. Litvan, I. Recent advances in atypical parkinsonian disorders. Curr Opin Neurol 1999;12(4):441–6.
40. Wadia, PM, Lang, AE. The many faces of corticobasal degeneration. Parkinsonism Relat Disord 2007;13(Suppl 3):S336–40.
41. Boeve, BF, Lang, AE, Litvan, I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003;54(Suppl 5):S1519.
42. Riley, DE, Lang, AE, Lewis, A, et al. Cortical-basal ganglionic degeneration. Neurology 1990;40:1203–12.
43. Lang, AE, Riley, DE, Bergeron, C. Cortical-basal ganglionic degeneration. In: Calne, DB, ed. Neurodegenerative Diseases. Philadelphia: W.B. Saunders. 1994;877–94.
44. Watts, RL, Mirra, SS, Richardson, EP. Cortical-basal ganglionic degeneration. In: Marsden, CD, Fahn, S, eds. Movement Disorders, Vol 3. Oxford: Butterworth Heinemann. 1994;282–99.
45. Kumar, R, Bergeron, C, Pollanen, M, Lang, AE. Cortical-basal ganglionic degeneration. In: Jankovic, J, Tolosa, E, eds. Parkinson's Disease & Movement Disorders. Baltimore: Williams & Wilkins. 1998;297316.
46. Litvan, I, Cummings, JL, Mega, M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998;65:717–21.
47. Bak, TH, Hodges, JR. Corticobasal degeneration: clinical aspects. Handb Clin Neurol 2008;89:509–21.
48. Hodges, JR, Davies, RR, Xuereb, JH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004;56 (3):399406.
49. Josephs, KA, Petersen, RC, Knopman, DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006;66 (1):41–8.
50. McMonagle, P, Blair, M, Kertesz, A. Corticobasal degeneration and progressive aphasia. Neurology 2006;67 (8):1444–51.
51. Massey, LA, Micallef, C, Paviour, DC, et al. Conven-tional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord 2012;27 (14):1754–62.
52. Massey, LA, Jäger, HR, Paviour, DC, et al. The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology 2013;80 (20):1856–61.
53. Quattrone, A, Nicoletti, G, Messina, D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008;246 (1):214–21.
54. Borroni, B, Malinverno, M, Gardoni, F, et al. A combination of CSF tau ratio and midsaggital midbrain-to-pons atrophy for the early diagnosis of progressive supranuclear palsy. J Alzheimers Dis 2010;22 (1):195203.
55. Cosottini, M, Ceravolo, R, Faggioni, L, et al. Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. Acta Neurol Scand 2007;116 (1):3742.
56. Duchesne, S, Rolland, Y, Vérin, M. Automated computer differential classification in parkinsonian syndromes via pattern analysis on MRI. Acad Radiol 2009;16 (1):6170.
57. Shi, HC, Zhong, JG, Pan, PL, et al. Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies. Neurol Sci 2013;34 (7):1049–55.
58. Padovani, A, Borroni, B, Brambati, SM, et al. Diffusion tensor imaging and voxel based morphometry study in early progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2006;77 (4):457–63.
59. Price, S, Paviour, D, Scahill, R, et al. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease. Neuroimage 2004;23 (2):663–9.
60. Agosta, F, Kostić, VS, Galantucci, S, et al. The in vivo distribution of brain tissue loss in Richardson's syndrome and PSP-parkinsonism: a VBM-DARTEL study. Eur J Neurosci 2010;32 (4):640–7.
61. Agosta, F, Pievani, M, Svetel, M, et al. Diffusion tensor MRI contributes to differentiate Richardson's syndrome from PSP-parkinsonism. Neurobiol Aging 2012;33 (12):2817–26.
62. Focke, NK, Helms, G, Scheewe, S, et al. Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic Parkinson syndrome and healthy controls. Hum Brain Mapp 2011;32 (11):1905–15.
63. Sajjadi, SA, Acosta-Cabronero, J, Patterson, K, et al. Diffusion tensor magnetic resonance imaging for single subject diagnosis in neurodegenerative diseases. Brain 2013;136:2253–61.
64. Ling, H, O'Sullivan, SS, Holton, JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010;133:2045–57.
65. Lee, SE, Rabinovici, GD, Mayo, MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011;70 (2):327–40.
66. Seeley, WW, Crawford, RK, Zhou, J, Miller, BL, Greicius, MD. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009;62 (1):4252.
67. Borroni, B, Garibotto, V, Agosti, C, et al. White matter changes in corticobasal degeneration syndrome and correlation with limb apraxia. Arch Neurol 2008;65 (6):796801.
68. Erbetta, A, Mandelli, ML, Savoiardo, M, et al. Diffusion tensor imaging shows different topographic involve-ment of the thalamus in progressive supranuclear palsy and corticobasal degeneration. Am J Neuroradiol 2009;30 (8):1482–7.
69. Whitwell, JL, Jack, CR, Boeve, BF, et al. Imaging correlates of pathology in corticobasal syndrome. Neurology 2010;75 (21):1879–87.
70. Borroni, B, Premi, E, Agosti, C, et al. CSF Alzheimer's disease-like pattern in corticobasal syndrome: evidence for a distinct disorder. J Neurol Neurosurg Psychiatry 2011;82 (8):834–8.
71. Oh, M, Kim, JS, Kim, JY, et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med 2012;53 (3):399406.
72. Srulijes, K, Reimold, M, Liscic, RM, et al. Fluorodeoxyglucose positron emission tomography in Richardson's syndrome and progressive supranuclear palsy-parkinsonism. Mov Disord 2012;27 (1):151–5.
73. Ceravolo, R, Rossi, C, Cilia, R, et al. Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: a SPECT follow-up study. Parkinsonism Relat Disord 2013;19 (5):557–9.
74. Urakami, K, Wada, K, Arai, H, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 2001;183 (1):95–8.
75. Borroni, B, Malinverno, M, Gardoni, F, et al. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 2008;71 (22):1796–803.
76. Bugiani, O, Murrell, JR, Giaccone, G, et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 1999;58(6):667–77.
77. Poorkaj, P, Muma, NA, Zhukareva, V, et al. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol 2002;52(4):511–16.
78. Pastor, P, Pastor, E, Carnero, C, et al. Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene. Ann Neurol 2001;49(2):263–7.
79. Ferrer, I, Pastor, P, Rey, MJ, et al. Tau phosphorylation and kinase activation in familial tauopathy linked to deln296 mutation. Neuropathol Appl Neurobiol 2003;29(1):2334.
80. Oliva, R, Pastor, P. Tau gene delN296 mutation, Parkinson's disease, and atypical supranuclear palsy. Ann Neurol 2004;55(3):448–9.
81. Rossi, G, Gasparoli, E, Pasquali, C, et al. Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene. Ann Neurol 2004;55(3):448.
82. Rojo, A, Pernaute, RS, Fontán, A, et al. Clinical genetics of familial progressive supranuclear palsy. Brain 1999;122:1233–45.
83. Ros, R, Thobois, S, Streichenberger, N, et al. A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy. Arch Neurol 2005;62(9):1444–50.